Quince Marks Final Patient Visit in NEAT Phase 3 Study
Quince Therapeutics Inc :QUINCE THERAPEUTICS ANNOUNCES LAST PATIENT LAST VISIT IN PHASE 3 NEAT CLINICAL TRIAL IN PATIENTS WITH ATAXIA-TELANGIECTASIAQUINCE THERAPEUTICS - EXPECTS TOPLINE RESULTS IN Q1 2026
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments